Therapy-related myeloid leukemia
Citation, DOI, disclosures and article data
At the time the article was created Bruno Di Muzio had no recorded disclosures.View Bruno Di Muzio's current disclosures
At the time the article was last revised Craig Hacking had no recorded disclosures.View Craig Hacking's current disclosures
Therapy-related myeloid leukaemias, also referred to as therapy-related myeloid neoplasms, occur as a late complication after cytotoxic therapies (e.g. chemotherapy, immunosuppressive therapy, and radiation therapy) performed to treat other conditions. They represent hematological malignancies where a causal relationship has been implied, and have been recognized as distinct entities by the WHO classification of tumors of hematopoietic and lymphoid tissues.
- therapy-related acute myeloid leukemia (t-AML)
- therapy-related myelodysplastic syndrome (t-MDS)
- therapy-related myelodysplastic syndrome/myeloproliferative neoplasms (t-MDS/MPN)
They are known to have poor outcomes compared to the de novo cases of these entities. For further discussion, please refer to the main articles of each myeloid neoplasm.
- 1. Godley LA, Larson RA. Therapy-related myeloid leukemia. (2008) Seminars in oncology. 35 (4): 418-29. doi:10.1053/j.seminoncol.2008.04.012 - Pubmed
- 2. Sabine Kayser, Konstanze Döhner, Jürgen Krauter, Claus-Henning Köhne, Heinz A. Horst, Gerhard Held, Marie von Lilienfeld-Toal, Sibylla Wilhelm, Andrea Kündgen, Katharina Götze, Mathias Rummel, David Nachbaur, Brigitte Schlegelberger, Gudrun Göhring, Daniela Späth, Carina Morlok, Manuela Zucknick, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk, for the German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. (2011) Blood. 117 (7): 2137. doi:10.1182/blood-2010-08-301713 - Pubmed